<?xml version="1.0" encoding="UTF-8"?>
<p>There are no randomized trial data to understand whether switching a patient from one product to another will change the risk of inhibitor formation. Inhibitors typically occur within the first 50 exposure days to factor in severe patients 
 <sup>
  <xref rid="ref-31" ref-type="bibr">31</xref>
 </sup>. Prior studies done after national health services required a change in FVIII product have found varied results 
 <sup>
  <xref rid="ref-32" ref-type="bibr">32</xref>â€“ 
  <xref rid="ref-36" ref-type="bibr">36</xref>
 </sup>. Consequently, providers who switch products do so carefully with inhibitor titers pre- and post-switch and generally avoid switching in patients with a history of inhibitor who have been tolerized with a specific product.
</p>
